Question 1

What are the most cited papers from June E. Nylen Cancer Center?

Accepted Answer

The most cited paper from June E. Nylen Cancer Center is "Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial" (Brian G.M. Durie, Antje Hoering, Muneer Hyder Abidi et al., 2016), with 911 citations. Next come "Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT)" (256) and "The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: results of a randomized phase III clinical trial" (173).

Question 2

Which research topics does June E. Nylen Cancer Center publish most on?

Accepted Answer

By volume in 2022-now: BRCA gene mutations in cancer, Brain Tumor Detection and Classification, Brain Metastases and Treatment and Glioma Diagnosis and Treatment.

Question 3

Which fields of science does June E. Nylen Cancer Center work in?

Accepted Answer

In all years, 68% of research at June E. Nylen Cancer Center is in Health Sciences, 18% in Social Sciences. Its largest fields are Medicine (55%), Psychology (10%), Health Professions (9%). It does 2.0× the world's share of Health Sciences.

Question 4

Is June E. Nylen Cancer Center's research output growing?

Accepted Answer

Output in 2022-2025 was 221% higher than in 2018-2021.